How do all the things that John and Bethany were just talking about, uh, affect antitrust strategy? G-what, what would it attract antitrust scrutiny?

Well, thanks, Wayne.

Uh, so just taking a, a step back, right, in terms of, uh, antitrust.

Uh, antitrust regulators are, you know, really simply put, they're, they're concerned with anything that reduces competition.

Uh, in the pharma space, you know, that may include things like, uh, artificially extending patent monopolies, uh, ac-actions that may thwart generic entry or, or even anything that influences drug price negotiation.

Uh, historically, uh, antitrust enforcers, uh, cared mostly about, you know, things like overlaps of commercialized products in pharma M&A or, or something like price fixing.

What's interesting about pharma today is that many current sources of antitrust risk aren't obviously problematic on their face.

What mistakes, and again, they're inadvertent by definition, what mistakes are your clients making that they could have avoided, but that got them into some problems?